[go: up one dir, main page]

SE408179B - Analogiforfarande for framstellning av imidazo(5,1-a)-as-triaziner - Google Patents

Analogiforfarande for framstellning av imidazo(5,1-a)-as-triaziner

Info

Publication number
SE408179B
SE408179B SE7400062A SE7400062A SE408179B SE 408179 B SE408179 B SE 408179B SE 7400062 A SE7400062 A SE 7400062A SE 7400062 A SE7400062 A SE 7400062A SE 408179 B SE408179 B SE 408179B
Authority
SE
Sweden
Prior art keywords
triazines
imidazo
preparation
analogical procedure
analogical
Prior art date
Application number
SE7400062A
Other languages
English (en)
Swedish (sv)
Inventor
R W Clarke
D Hartley
A W Oxford
Original Assignee
Allen & Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen & Hanburys Ltd filed Critical Allen & Hanburys Ltd
Publication of SE408179B publication Critical patent/SE408179B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE7400062A 1973-01-04 1974-01-03 Analogiforfarande for framstellning av imidazo(5,1-a)-as-triaziner SE408179B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB55373*[A GB1457873A (en) 1973-01-04 1973-01-04 Imidazotriazines

Publications (1)

Publication Number Publication Date
SE408179B true SE408179B (sv) 1979-05-21

Family

ID=9706420

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7400062A SE408179B (sv) 1973-01-04 1974-01-03 Analogiforfarande for framstellning av imidazo(5,1-a)-as-triaziner

Country Status (19)

Country Link
US (1) US3941785A (de)
JP (1) JPS4995994A (de)
AT (1) AT336029B (de)
AU (1) AU474078B2 (de)
BE (1) BE809369A (de)
CA (1) CA1005057A (de)
CH (1) CH618170A5 (de)
DE (1) DE2364076A1 (de)
ES (1) ES422001A1 (de)
FI (1) FI57260C (de)
FR (1) FR2213058B1 (de)
GB (1) GB1457873A (de)
IE (1) IE38681B1 (de)
IL (1) IL43872A (de)
LU (1) LU69099A1 (de)
NL (1) NL7400095A (de)
NO (1) NO140301C (de)
SE (1) SE408179B (de)
ZA (1) ZA739534B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4107309A (en) * 1977-05-23 1978-08-15 American Cyanamid Company Substituted imidazo[1,2-d]-as-triazines
US4096257A (en) * 1977-05-23 1978-06-20 American Cyanamid Company Substituted imidazo [1,2-d]-as-triazines
US4126444A (en) * 1977-11-22 1978-11-21 American Cynamid Company Substituted imidazo (1,5-D)-as-triazin-4-ols, and herbicidal use thereof
US4308384A (en) * 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
DD244681A3 (de) * 1985-12-02 1987-04-15 Zeiss Jena Veb Carl Vorrichtung zur positionierung von enden flexibler lichtleitelemente
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
EP2295436A1 (de) * 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
CA2341488A1 (en) 1998-08-26 2000-03-09 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
HU229439B1 (hu) * 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
DE50209015D1 (de) * 2001-05-09 2007-02-01 Bayer Healthcare Ag NEUE VERWENDUNG VON 2-Ä2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenylÜ-5-methyl-7-propyl-3H-imidazoÄ5,1-fÜÄ1,2,4Ütriazin-4-on
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
GB0113344D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
WO2004087652A2 (en) * 2003-04-01 2004-10-14 Smithkline Beecham Corporation Imidazotriazine compounds
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (de) * 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2167057A1 (de) * 2007-06-13 2010-03-31 Bayer HealthCare AG Pde-hemmer zur behandlung von gehörschäden
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques

Also Published As

Publication number Publication date
AU474078B2 (en) 1976-07-15
CA1005057A (en) 1977-02-08
GB1457873A (en) 1976-12-08
NO140301C (no) 1979-08-08
IE38681L (en) 1974-07-04
CH618170A5 (de) 1980-07-15
FI57260C (fi) 1980-07-10
FR2213058A1 (de) 1974-08-02
AT336029B (de) 1977-04-12
BE809369A (fr) 1974-07-03
FR2213058B1 (de) 1977-07-01
IE38681B1 (en) 1978-05-10
DE2364076A1 (de) 1974-07-18
JPS4995994A (de) 1974-09-11
FI57260B (fi) 1980-03-31
US3941785A (en) 1976-03-02
NL7400095A (de) 1974-07-08
LU69099A1 (de) 1974-04-02
ATA2374A (de) 1976-08-15
ES422001A1 (es) 1976-08-01
NO140301B (no) 1979-04-30
AU6377473A (en) 1975-06-19
ZA739534B (en) 1974-11-27
IL43872A0 (en) 1974-03-14
IL43872A (en) 1979-01-31

Similar Documents

Publication Publication Date Title
SE408179B (sv) Analogiforfarande for framstellning av imidazo(5,1-a)-as-triaziner
SE423631B (sv) Forfarande for framstellning av oxaalhyl-dialkylxantiner
SE390819B (sv) Analogiforfarande for framstellning av piperazinyl-propyl-1,2,4-triazolinderivat
SE7710600L (sv) Forfarande for framstellning av 1,3-bensoxazoler
SE411212B (sv) Forfarande for framstellning av 3-halogen-cefalosporiner
NO146596C (no) Fremgangsmaate for fremstilling av 6-deoksytetracykliner
SE417601B (sv) Forfarande for framstellning av amidinokarbamider
NO790627L (no) Fremgangsmaate for fremstilling av hydroksyalkylxantiner
DK133051C (da) Analogifremgangsmade til fremstilling af 1,3-oxygenerede 8alfa-ostratriener
NO843825L (no) Fremgangsmaate for fremstilling av 6-deoksytetracyklin
DK132707C (da) Analogifremgangsmade til fremstilling af 1,3,16,17-tetraoxygenerede 8alfa-ostratriener
SE409716B (sv) Analogiforfarande for framstellning av 11beta-alkyl-deltaŸ4-estrener
SE408552B (sv) Analogiforfarande for framstellning av nya pyrazoloner-(5)
SE426242B (sv) Analogiforfarande for framstellning av 1,4-bensodiazepinderivat
SE431451B (sv) Forfarande for framstellning av 2,3-dihydroxipropoxikinoliner eller -isokinoliner
SE421693B (sv) Forfarande for framstellning av n-substituerade 1-amino-3-fenoxi-propanoler-(2)
SE428015B (sv) Forfarande for framstellning av 3.4-dihydrokarbostyrilderivat
SE398501B (sv) Analogiforfarande for framstellning av 1,4-bensodiazepinderivat
SE420603B (sv) Forfarande for framstellning av metyl-3-(2-kinoxolinylmetylen)-karbazat-n?721, n?724-dioxid
SE409994B (sv) Forfarande for framstellning av amidinokarbamider
SE411211B (sv) Forfarande for framstellning av 3-halogencefalosporiner
SE388611B (sv) Analogiforfarande for framstellning av 1,4-bensodiazeponderivat
NO139125C (no) Analogifremgangsmaate for fremstilling av cykloheksantetrolderivater
SE398122B (sv) Analogiforfarande for framstellning av pyrazino/1,2-a/indol-2-karboxamidiner
BG23006A3 (bg) Метод за получаване на имидазо-(1,2-а)-сим.-триазини